ReviewClinical and experimental immunology2019
Emerging viruses and current strategies for vaccine intervention.
Review in Clinical and experimental immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global epidemiology, viral evolution, and public health responses: a systematic review on Mpox (1958-2024).Journal of global health · 2025Pooled it
- A systematic review of SARS-CoV-2 vaccine candidates.Signal transduction and targeted therapy · 2020Pooled it
- Review
- Extracellular vesicles: Antiviral functions and applications in therapeutics and vaccines.iScience · 2025Review
- Contagious ecthyma in small ruminants: from etiology to vaccine challenges - a review.Veterinary research communications · 2025Review
- VirusImmu: a novel ensemble machine learning approach for viral immunogenicity prediction.Briefings in functional genomics · 2025Article
- Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection.Viruses · 2024Article
- Assessment of Italian Population Awareness on One-Health, Zoonoses and the Mpox Vaccine: A Nationwide Cross-Sectional Study.Vaccines · 2024Article
- Development of nucleic acid-based vaccines against dengue and other mosquito-borne flaviviruses: the past, present, and future.Frontiers in immunology · 2024Review
- Clinical Characteristics, Diagnosis, and Therapeutics of COVID-19: A Review.Current medical science · 2023Review
- Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines.Pathogens (Basel, Switzerland) · 2023Review
- mAb therapy controls CNS-resident lyssavirus infection via a CD4 T cell-dependent mechanism.EMBO molecular medicine · 2023Article
- HPV pathogenesis, various types of vaccines, safety concern, prophylactic and therapeutic applications to control cervical cancer, and future perspective.Virusdisease · 2023Review
- The inactivation and destruction of viruses by reactive oxygen species generated through physical and cold atmospheric plasma techniques: Current status and perspectives.Journal of advanced research · 2023Review
- Ethnopharmacological Potential of Phytochemicals and Phytogenic Products against Human RNA Viral Diseases as Preventive Therapeutics.BioMed research international · 2023Review
- Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil.Vaccine · 2022Article
- Antiviral potential of nanoparticles for the treatment of Coronavirus infections.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2022Review
- Toward rational vaccine engineering.Advanced drug delivery reviews · 2022Review
- Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2.PLoS computational biology · 2022Article
- Plant-Based Vaccines in Combat against Coronavirus Diseases.Vaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the past decade several notable viruses have suddenly emerged from obscurity or anonymity to become serious global health threats, provoking concern regarding their sustained epidemic transmission in immunologically naive human populations. With each new threat comes the call for rapid vaccine development. Indeed, vaccines are considered a critical component of disease prevention for emerging viral infections because, in many cases, other medical options are limited or non-existent, or that infections result in such a rapid clinical deterioration that the effectiveness of therapeutics is limited. While classic approaches to vaccine development are still amenable to emerging viruses, the application of molecular techniques in virology has profoundly influenced our understanding of virus biology, and vaccination methods based on replicating, attenuated and non-replicating virus vector approaches have become useful vaccine platforms. Together with a growing understanding of viral disease emergence, a range of vaccine strategies and international commitment to underpin development, vaccine intervention for new and emerging viruses may become a possibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.